Arrowstreet Capital Limited Partnership Cuts Stake in Edwards Lifesciences Co. (NYSE:EW)

Arrowstreet Capital Limited Partnership cut its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 48.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,988 shares of the medical research company's stock after selling 43,796 shares during the period. Arrowstreet Capital Limited Partnership's holdings in Edwards Lifesciences were worth $3,404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $54,000. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,853 shares of company stock valued at $4,534,247 in the last ninety days. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Piper Sandler boosted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday. Morgan Stanley boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $78.55.

Edwards Lifesciences Stock Up 0.9 %

Edwards Lifesciences stock traded up $0.62 during trading hours on Monday, reaching $70.02. The stock had a trading volume of 220,195 shares, compared to its average volume of 4,895,899. The company has a market cap of $41.16 billion, a price-to-earnings ratio of 9.99, a PEG ratio of 4.82 and a beta of 1.15. The business's 50 day moving average price is $71.32 and its 200-day moving average price is $70.74. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.